Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SHR-1314 Formulations in Healthy Subjects
NCT04326881Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of vunakizumab in plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) (3 arms), sponsored by Hengrui. Primary endpoints: Area under the serum concentration-time curve from time zero to the last measurable concentration, Observed maximum serum concentration and 1 more. Status: unknown.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04326881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326881.